Register for real-time alerts, custom portfolio, and market movers
| Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
|---|---|---|---|---|---|
| Oxford Cannabinoid Technologies Holdings Plc | LSE:OCTP | London | Ordinary Share | GB00BMVMRB86 | ORD GBP0.001 |
| Price Change | % Change | Share Price | Shares Traded | Last Trade
|
|
|---|---|---|---|---|---|
| 0.00 | 0.00% | 0.115 | 0.00 | 00:00:00 |
| Bid Price | Offer Price | High Price | Low Price | Open Price | |
|---|---|---|---|---|---|
| 0.10 | 0.13 | ||||
| Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
|---|---|---|---|---|---|
| Coml Physical, Biologcl Resh | -5.95M | -0.0062 | -0.18 | 1.1M |
| Last Trade Time | Trade Type | Trade Size | Trade Price | Currency |
|---|---|---|---|---|
| - | O | 0 | 0.115 | GBX |
| Date | Time | Source | Headline |
|---|---|---|---|
| 06/6/2024 | 07:00 | UK RNS | London Stock Exchange Notice Cancellation - Oxford Cannabinoid Tech Hldgs.. |
| 06/6/2024 | 07:00 | UK RNS | Official List Removal - Oxford Cannabinoid Tech Holdings Plc |
| 06/6/2024 | 06:00 | UK RNS | Oxford Cannabinoid Tech.Holdings Cancellation of Listing |
| 31/5/2024 | 06:00 | UK RNS | Oxford Cannabinoid Tech.Holdings Updated Shareholder Engagement |
| 17/5/2024 | 20:45 | ALNC |  IN BRIEF: Oxford Cannabinoid says it remains bound by Takeover Code |
| 17/5/2024 | 15:30 | UK RNS | Oxford Cannabinoid Tech.Holdings Updated Shareholder Information |
| 08/5/2024 | 13:27 | ALNC | Oxford Cannabinoid shares plummet following delisting request |
| 08/5/2024 | 06:00 | UK RNS | Oxford Cannabinoid Tech.Holdings Intended Cancellation of Listing |
| 11/4/2024 | 12:18 | ALNC | Oxford Cannabinoid teams with iNGENu to test OCT130401 pain treatment |
| 11/4/2024 | 10:26 | UK RNS | Oxford Cannabinoid Tech.Holdings Appointment of Phase I Clinical Trial CRO |
Oxford Cannabinoid Techn... (OCTP) Share Charts1 Year Oxford Cannabinoid Techn... Chart |
|
1 Month Oxford Cannabinoid Techn... Chart |
Intraday Oxford Cannabinoid Techn... Chart |
| Date | Time | Title | Posts |
|---|---|---|---|
| 01/10/2024 | 05:53 | Oxford cannabinoid technologies | 480 |
| 21/5/2023 | 19:07 | Oxford cannabinoid with charts | 490 |
| Trade Time | Trade Price | Trade Size | Trade Value | Trade Type |
|---|
| Top Posts |
|---|
Posted at 21/11/2024 08:20 by Oxford Cannabinoid Techn... Daily Update Oxford Cannabinoid Technologies Holdings Plc is listed in the Coml Physical, Biologcl Resh sector of the London Stock Exchange with ticker OCTP. The last closing price for Oxford Cannabinoid Techn... was 0.12p.Oxford Cannabinoid Techn... currently has 960,415,644 shares in issue. The market capitalisation of Oxford Cannabinoid Techn... is £1,056,457. Oxford Cannabinoid Techn... has a price to earnings ratio (PE ratio) of -0.18. This morning OCTP shares opened at - |
Posted at 31/5/2024 23:22 by sep800 Does anyone here have any faith for the future of this company once it delist ?I am still on the side lines wether to sell my holding or hold. Never keen to sell at a loss at this level but at the same time can we trust the board that existing holders will be protected although technically share will be worth zero without able to trade. Are we selling or holding ? Comments welcome |
Posted at 08/5/2024 16:45 by isis They've been burning Cash like Bob Marley used to burn Spliff's as far as I can make out!Financial Highlights -- Robust balance sheet, debt-free with cash reserves of approximately GBP2.3m at year-end (30 April 2022: GBP9.2m). Cash is forecast to be fully utilised by April 2024. -- Cash absorbed by operations of GBP7.0m (FY2022: GBP5.4m); Loss for year of GBP5.9m (30 April 2022: GBP4.7m). -- Basic and diluted loss per share of (0.62p) (30 April 2022: 0.49p loss). -- Cost savings continued, including closure of London office in April 2022, expected to generate savings of approximately GBP130k p.a. -- Research costs (excluding salary costs) increased in line with budget to GBP4.3m (30 April 2022: GBP2.9m), of which GBP2.0m relates to OCT461201 and GBP1.9m on OCT130401. A further GBP0.4m was spent on Programmes 3 and 4 mainly relating to the development of CB1/CB2 agonists by Dalriada . -- Operational costs increased from GBP2.3m to GBP2.7m, including salaries and associated costs of GBP1.4m. -- Exceptional items of GBP0.1m (30 April 2022: GBP0.3m) relate to share based (non-cash) payment charges. R&D tax credit in the period of GBP1.1m (30 April 2022: GBP0.8m), with tax losses surrendered for the R&D tax credit payment. |
Posted at 28/2/2024 17:41 by sep800 Not great news with major share holders reducing their stake.CEO.... we are losing confidence here ! |
Posted at 26/2/2024 14:05 by burtond1 Director Dealings. Raise was at .5 remember https://www.londonst |
Posted at 15/1/2024 16:01 by sep800 Over the last few months we have been seeing the share price sold into around 0.7 - 0.75p.Are we witnessing an internal share agreement or an institution on an approved funding agreement ? DGI had a deal with three 3 new directors raising £2.4M with share allocation. Are we seeing the same here ? Too many 500K 750K & 1M blocks being sold We know OCTP were looking to fund their future assets towards end Q1 2024. Maybe we may get an announcement that funding has been completed taking OCTP to production |
Posted at 29/9/2023 14:06 by sep800 Very quite on here lately. Not long for confirmation of phase 1 complete. I think we have been hinted that no adverse effect therefore expecting phase 2 fairly soon. Been a long road since IPO and the share price needs some recovery. However at this level take advantage of the very low current share price Funded till next April 2024 and expect a JV or share offer to existing shareholders at a much higher level than currently. Plenty other products in the pipeline and I would expect OCTP would be a great performer during 2024.GLA |
Posted at 28/7/2023 23:05 by sep800 OCTP about to turn heads with its trials, They are still on for results Q3. Once the news confirms the drug is safe and without serious side effects it will roll on to Phase 2.This phase 1 results will surge OCTP closer to being one of those rare successful Pharmaceutical companies that their R&D actually pays dividends. @ £9M M/C will be long gone. Glad to be on board at such an early stage of success. Plenty news flow to follow. We are also seeing the price being suppress for some large buy orders, most sells are buys and with 2x 6M and 2M recent buys shows confidence. I just can't see the share price going down any further especially with recent Videos and announcements. MM's will have to let this go GLA |
Posted at 10/7/2023 15:22 by sep800 If you have researched properly what company you decide to invest in then OCTP has all the products to be fruitful. OCTP is not for day trading at this stage, nevertheless there are opportunities when the share price has fallen well below the value of a company that one should consider a time to buy or top-up. At this level it's a buy, especially with news of its phase 1 trials due. OCTP do not need to raise and still have £5M cash and are fully funded for its trials and research till 2024.All to their own, but patients will be rewarded. Buy, leave in a bottom drawer and come back next year, or trade on news GL |
Posted at 05/1/2023 15:44 by sep800 OCTP have come along way since the IPO 18 months ago, And the markets at that time 5p was a sensible value. Since then OCTP have incurred the usual drop in the share price due to lack of activity as most companies sort their admin out in the first 12 months together with the markets shorting the share price as a safe calculated risk due to the given factors.However £0.005p was well over done and the Markets have now u-turned as OCTP gain advantages from its trials with a product well known to the medical industry. We are now going to see the share price raise to a more suitable level especially given the commencement of the trials, With £5M cash which means no fund raising this year. We have so much news to follow very soon and with OCTP on track to deliver a product this year, I see no reason why the share price short term to be 2.5p-3p moving up on further positive news. Certainly plenty of up side from here and one to hold onto at least prior to results. Any positive news will accelerate the share price northwards and with just A small amount of free float shares available, the share price will rise quickly just as we have seen in the last week. I believe the MM's got caught out last week and are trying to force sellers to balance their books, however if there are no sellers to share price will keep rising. Either way I believe we are in a good position ready for any positive news to land. GLA |
Posted at 05/1/2023 15:37 by sep800 OCTP have come along way since the IPO 18 months ago, And 5p was a sensible value. Since then OCTP have incurred the usual drop in the share price due to lack of activity as most companies sort their admin out in the first 12 months together with the markets shorting the share price as a safe calculated risk due to the given factors.However £0.005p was well over done. As OCTP gain advantages from its trials with a product well known to the medical industry,We are now going to see the share price raise to a more suitable level especially given the commencement of the trials together with £5M cash which means no fund raising this year. So much news to follow and on track to deliver a product this year, I see no reason way the share price short term be 2.5p-3p moving up on further positive news. Certainly plenty of up side from here and one to hold onto at least prior to results. Any positive news will accelerate the share price northwards with small amount of free float shares available, the share price will rise quickly just as we have seen in the last week. I believe the MM's got caught out last week and are trying to force sellers to balance their books, however if there are no sellers to share price will keep rising. Get ready for positive news to land. GL |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
